Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Retamol is a branded generic formulation of paracetamol (acetaminophen) developed and marketed by SNIG Pharma. It is a small molecule non-opioid analgesic and antipyretic used for the management of mild to moderate pain and the reduction of fever. Retamol is particularly indicated for short-term treatment in clinical settings, such as post-operative care, where rapid relief is required or oral administration is not feasible. The drug's mechanism of action involves the inhibition of prostaglandin synthesis within the central nervous system and a direct effect on the hypothalamic heat-regulating center to produce antipyresis. It is commonly available as a 1000 mg intravenous infusion, providing a high-dose, fast-acting alternative to oral paracetamol formulations.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Retamol.